Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatment of patients with Post- Lyme syndrome
Ritchie C. Shoemaker, Bullano K2000
Endocrine (ADH/ACTH/MSH)Immune/InnateNeurological
Lyme & Co-Infections
Summary
No abstract is available for this paper. It was published in 2000 by Ritchie C. Shoemaker and colleagues. CIRS Nexus tags it under Lyme & Co-Infections, Endocrine (ADH/ACTH/MSH), Immune/Innate, Neurological.
Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady
Related Papers
- Herbal Therapeutics for CIRS Biomarkers in Autism Spectrum Disorders: A Mechanistic and Molecular Approach for Neuroimmune Pathology in PediatricsMedical Research Archives · 2026 · 4 shared tags
- Chronic Fatiguing Illnesses: Entering the era of new biomarkers and therapiesInternal Medicine Review · 2017 · 4 shared tags
- TUBB1, TUBA4A and MAPK as Indicators of Die-Back Degenerative Central Nervous System Disease in Patients Sickened by Specific Exposure to the Interior Environment of Water- Damaged BuildingsMedical Research Archives · 2023 · 4 shared tags
- Autism Spectrum Disorders and Lyme Disease: Exploring Shared Neuro-Inflammatory and Immune PathwaysMedical Research Archives · 2025 · 4 shared tags
- Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illnessThe Pediatric Infectious Disease Journal · 1997 · 4 shared tags
- Therapeutic and preventive interventions for postulated vasoactive neuropeptide autoimmune fatigue-related disordersMedical Hypotheses · 2005 · 4 shared tags